It's been a rocky few months for Novo Nordisk.Prescription data from IQVIA suggests Novo's obesity drug Wegovy is losing ground…
Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20%. Source link
Weight-loss businesses, which long pushed calorie-counting and willpower, are grappling with the surging popularity of new drugs. Source link